吲哒帕胺联合比索洛尔治疗原发性高血压患者的疗效观察

目的：探讨小剂量吲哒帕胺联合比索洛尔治疗原发性高血压患者的安全性和疗效。方法：60例初诊的高血压Ⅰ级、Ⅱ级患者,随机分为治疗组及对照组。治疗组予以吲哒帕胺2.5mg/次,及比索洛尔2.5mg/次,每天早晨7时服药1次;对照组单用吲哒帕胺2.5mg/次,每天早晨7时口服1次,疗程8周。结果：两组患者血压（收缩压及舒张压）均有下降,但以治疗组血压下降明显。治疗组显效13例,有效14例;对照组显效8例,有效15例;治疗组总有效率为90%,治疗组无效率为10%;对照组有效率76.7%,无效率23.3%,2组疗效差异有统计学意义（P〈0.05）。两组不良反应相似,治疗前后生化指标变化差别无统计学意义。结论：比索洛尔联合吲哒帕胺治疗原发性高血压安全有效,对糖、脂代谢无明显影响。

Effects of Bisorpolol and Indapamide Combination Therapy on Blood Pressure in the Patients with Mild to Moderate Essential Hypertension

Objective： To evaluate the safety and efficiency of bisorpolol （Stag, Qd） and indapamide （2.5 mg, Qd） combination therapy in treating patients with mild to moderate essential hypertension. Methods： Sixty patients with mild to moderate essential hypertension were randomly divided into 2 groups （A and B）. Patients in group A took bisoprolol （5 mg, Qd） combining with indapamide （2. 5 mg, Qd）, and patients in group B took indapamide （2.5mg, Qd） only for 8 weeks. All the patients were finished the trial. Blood pressure （BP） and biochemical markers were observed. Results： At the 8th week, thirteen patients had evident effect and fourteen patients had effect in group A, correspondingly, there was seven patients and sixteen patients in group B;The total antihypertensive effective rate was 90. 0% in group A and 76.7% in group B. The difference had statistical significance （P〈0. 05）. The biochemical, markers were not statistically significant before and after treatment. The incidence of side effects in the two groups were similar. Conclusion： Combination of bisorpolol and indapamide is not only effective and safe, but also no any influence on metabolism of lipids and glucose in treating patients with essential hypertension.